Evogene

Company Overview

Snapshot

Founded in January 2002 by Rafi Meissner and Hagai Karchi, Evogene operates with 51–200 employees. The company has raised a total of $135.7 million across 10 funding rounds from 9 investors. In August 2024, Evogene announced the pricing of a $5.5 million registered direct offering.

Business overview

Evogene is a computational biology company that leverages its Computational Predictive Biology (CPB) platform to drive product discovery and development across various life science industries, including human health and agriculture. The CPB platform integrates deep biological understanding with big data and artificial intelligence to computationally identify and guide the creation of life science products based on microbes, small molecules, and genetic elements. Through its subsidiaries, Evogene is advancing product pipelines in human microbiome-based therapeutics (Biomica Ltd), medical cannabis (Canonic Ltd), agricultural biologicals (Lavie Bio Ltd), agricultural chemicals (AgPlenus Ltd), and castor oil production solutions (Castera Ltd). The company operates within the Health Tech & Life Sciences sector, with a focus on sustainable farming, ag tech, and pharmaceuticals.

Strategic signal

In October 2024, Evogene announced a collaboration with Google Cloud to develop a generative AI foundation model for novel small molecule design. This partnership signals a strategic move to enhance its computational predictive biology platform with advanced AI capabilities, potentially accelerating drug discovery and development processes and strengthening its position in the competitive life sciences and pharmaceutical sectors.

Company Intelligence Q&A

What was a significant recent collaboration for Evogene?

In October 2024, Evogene announced a collaboration with Google Cloud to pioneer a generative AI foundation model for novel small molecule design, aiming to revolutionize product discovery in life sciences.

What was Evogene's most recent funding activity?

In August 2024, Evogene announced the pricing of a $5.5 million registered direct offering.

What recent grant did Lavie Bio, an Evogene subsidiary, receive?

In September 2024, Lavie Bio received a grant from the Israel Innovation Authority to advance the development of 'MicroFermentor' technology, which aims to improve the economics of agricultural biologicals.

What was a recent operational milestone for Casterra, an Evogene subsidiary?

In October 2024, Casterra announced the completion of its first shipment of castor seeds grown and processed in Kenya, marking a key milestone in its operational expansion plan in Africa.

What was the outcome of the collaboration between Watershed AC, Evogene, and Ben-Gurion University?

In October 2024, Watershed AC, Evogene, and Ben-Gurion University received approval for a second-year grant to continue their collaboration focused on improving crustacean traits utilizing gene-editing technology.